Drug Discovery11

💡 Artificial Intelligence & Machine Learning

Google Threat Intelligence Uncovers AI-Enabled Malware in Active Operations

November 4–6, 2025

In a pivotal security milestone, Google's Threat Intelligence Group (GTIG) released its "AI Threat Tracker" report, documenting a significant shift in adversarial AI misuse. For the first time, researchers identified malware families employing LLMs during execution to dynamically alter behavior mid-operation—a technique dubbed "Just-in-Time" AI. State-sponsored threat actors from North Korea, Iran, and China are now actively leveraging generative AI for reconnaissance, phishing campaigns, credential theft, and evasion of detection systems. The report highlights the emergence of sophisticated underground marketplaces offering AI tools specifically designed for cybercriminal operations.

Cybersecurity Threat Intelligence Read Google's Full GTIG Report

AlphaFold 3 Clinical Integration Reaches 95% Accuracy in Protein-Drug Interactions

November 5, 2025

Google DeepMind's AlphaFold 3 has now achieved clinical-grade integration for predicting protein structure and protein-drug interactions with 95% accuracy. This breakthrough accelerates drug target identification from years to weeks, with research teams across multiple institutions now actively employing the technology for molecular disease understanding. The system's capability to predict how drugs interact with human proteins represents a critical advance in precision oncology and personalized medicine development.

AI Drug Discovery Structural Biology DeepMind Updates

EU Launches €1 Billion "Apply AI Strategy" for Strategic Sectors Including Healthcare

November 2025

The European Commission unveiled a comprehensive €1 billion initiative to accelerate AI adoption across 10 strategic sectors, prominently featuring healthcare, manufacturing, energy, and defence. The "Apply AI Strategy" encourages an AI-first policy approach and promotes open-source AI solutions with a focus on European technological sovereignty. Notably, the EU is establishing RAISE (Resource for AI Science in Europe), a virtual institute to support scientists in leveraging AI capabilities, with a pilot version launching in November 2025 and full operationalization targeted for 2028.

Policy Healthcare AI EU AI Sovereignty Initiative

AI Drug Discovery Success Rates Exceed Traditional Methods by 2-3 Fold

November 2025

Recent analysis confirms that AI-assisted drug discovery programs demonstrate Phase I clinical success rates of 80–90%, substantially higher than traditional success rates of ~54%. Phase II success for AI-driven candidates reaches ~40%, compared to 34% historically. This evidence is driving accelerated investment, with AI startups capturing a record 53% of all venture capital funding globally in 2025—approximately $192.7 billion. The therapeutic development paradigm is fundamentally shifting toward data-driven, algorithmic target identification and molecular optimization.

Drug Development Clinical Success AI CRO Innovations

🧬 Gene Therapy & Cell Therapy

Beam Therapeutics' BEAM-101 Base-Edited Cell Therapy Advances Ahead of ASH 2025 Presentation

November 3, 2025

Beam Therapeutics announced that updated safety and efficacy data from the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified ex vivo cell therapy for severe vaso-occlusive crises in sickle cell disease (SCD), will be presented at the 67th American Society of Hematology (ASH) Annual Meeting (December 6–9, 2025, Orlando). BEAM-101 employs base editing technology—a precision genetic medicine approach distinct from traditional CRISPR—to create disease-modifying, one-time therapeutic interventions. Dr. Amy Simon, Chief Medical Officer of Beam, emphasized the potential to offer a "best-in-class gene editing approach for SCD," addressing the needs of the ~8 million individuals globally living with this condition.

Genetic Medicine Sickle Cell Disease Beam Therapeutics Press Release

Caribou's Allogeneic CAR-T Therapy CB-010 Achieves 86% Overall Response Rate in Lymphoma

November 2-3, 2025

Caribou Biosciences released compelling data from the ANTLER trial demonstrating that vispa-cel (CB-010), an allogeneic CAR-T cell therapy targeting CD19+ B-cell lymphomas, achieved an 86% overall response rate (ORR) with a 63% complete response (CR) rate in heavily treated patients. The optimized-profile cohort of 35 patients exhibited 53% progression-free survival at 12 months, matching durability benchmarks established by autologous CAR-T therapies. Critically, vispa-cel demonstrates safety and tolerability compatible with outpatient administration, potentially broadening access to transformative cell therapy for patients ineligible for autologous CAR-T or transplantation.

Cell Therapy Oncology Caribou ANTLER Trial Results

FDA Releases Draft Guidance on Postapproval Studies for Cell and Gene Therapies

November 5, 2025

The FDA's Center for Biologics Evaluation and Research (CBER) issued three new draft guidance documents to facilitate postapproval studies of cell and gene therapies: (1) Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; (2) Innovative Designs for Clinical Trials in Small Populations; and (3) Postapproval Methods for Safety and Efficacy Data Capture. The updated Expedited Programs guidance expands the definition of "regenerative medicine therapy" to explicitly include human gene therapies and xenotransplantation products. Comment periods remain open through November 24, 2025. These guidances are anticipated to align with a proposed new "plausible mechanism" pathway for rare disease CGT products to accelerate market access.

FDA Guidance Regulatory Affairs FDA Guidance Document Search

Latus Bio Launches AI/ML Strategy for AAV Capsid Engineering and Peptide Design

November 3, 2025

Latus Bio announced the launch of its formal AI/ML initiative to accelerate adeno-associated virus (AAV) gene therapy discovery and optimization. The company is leveraging large in vivo non-human primate (NHP) datasets to train machine learning models for AAV capsid tropism prediction and optimized payload design. The strategy includes recruitment of expert scientific advisors—Drs. Chatterjee and Kim—specializing in peptide and protein modeling. This integration of AI-driven protein engineering with empirical primate data exemplifies next-generation platform innovation in liver and extra-hepatic AAV delivery.

AI-Driven Discovery Gene Delivery Latus Bio AI/ML Initiative

⚛️ Radioligand Therapy & Theranostics

PSMAddition Trial: 177Lu-PSMA-617 (Pluvicto) Reduces Progression Risk by 28% in Hormone-Sensitive Prostate Cancer

October 17–21, 2025 (ESMO Congress); November 2025 Updates

The landmark phase 3 PSMAddition trial demonstrated that adding Pluvicto (177Lu-PSMA-617) to standard-of-care androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitor (ARPI) therapy significantly improved radiographic progression-free survival (rPFS) in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The hazard ratio of 0.72 (95% CI 0.58–0.90; p=.002) represents a 28% reduction in disease progression risk. At median follow-up of 23.6 months, 87.4% of patients in the 177Lu-PSMA-617 arm achieved PSA nadir <0.2 ng/mL versus 74.9% in the control arm. Critically, this represents the first phase 3 evidence for any targeted radionuclide therapy in chemotherapy-naive mHSPC, potentially expanding eligible patient populations by ~3-fold.

PSMA Therapy Prostate Cancer Phase 3 Trial PSMAddition Trial Data (ASCO)

SBRT + PSMA-Targeted Radioligand Therapy Delays Progression in Recurrent Prostate Cancer

September 2025 (ASTRO); Updated November 2025

The UCLA-led randomized trial, presented at the 2025 American Society for Radiation Oncology Annual Meeting, demonstrated that combining PSMA-targeting radioligand therapy with stereotactic body radiotherapy (SBRT) significantly delayed radiographic disease progression in recurrent prostate cancer. Median time to progression extended to 17.6 months with combined therapy versus 7.4 months with SBRT alone—a clinically meaningful delay that defers the need for hormonal therapy and its associated morbidities. Dr. Amar Kishan emphasized the "first randomized trial" status and the proof-of-principle for earlier radioligand intervention to modify disease trajectory.

Combination Therapy Recurrent Disease UCLA Health Announcements

Tandem Radioligand Therapy (177Lu/225Ac-PSMA) Demonstrates Enhanced Efficacy and Safety Profile

October 31, 2025 (Publication)

Recent clinical analysis of combined 177Lu/225Ac-PSMA tandem radioligand therapy (combining beta-emitter lutetium-177 with alpha-emitter actinium-225) shows promising efficacy and favorable safety outcomes. The dual-isotope approach leverages complementary radiation physics—beta particles for broader tumor penetration and alpha particles for enhanced localized cytotoxicity—to overcome resistance mechanisms. Assessment of PSMA expression intensity on pretherapeutic PET imaging was identified as a key predictor of treatment response, supporting personalized patient selection strategies. This represents an evolution toward hybrid alpha-beta radioligand therapy in precision oncology.

Targeted Alpha Therapy Theranostics Journal of Nuclear Medicine

SSTR2-Targeted Ac-225 DOTATATE Shows Near-Complete Response in Metastatic ER+ Breast Cancer

2024–2025 (Ongoing Clinical Observations)

Clinical case reports continue to document remarkable responses with somatostatin receptor 2 (SSTR2)–targeted radioligand therapy using actinium-225 (Ac-225) DOTATATE in heavily pretreated metastatic ER-positive breast cancer patients. One patient with Krenning score 4 DOTATATE uptake achieved near-complete radiographic response. Although not yet FDA-approved, these findings highlight off-label therapeutic potential in SSTR2-expressing malignancies beyond neuroendocrine tumors. Prospective trials are urgently needed to explore SSTR2-targeted theranostics in breast cancer, particularly for hormone-refractory disease.

Breast Cancer Alpha-Emitter RLT Radiology Journal

📊 Week-at-a-Glance Key Metrics

95%

AlphaFold 3 Accuracy in Protein-Drug Predictions

28%

Risk Reduction: 177Lu-PSMA-617 + ADT/ARPI (PSMAddition)

86%

Overall Response Rate: Caribou CB-010 CAR-T

80–90%

AI-Driven Drug Phase I Clinical Success Rate

🎯 This Week in Perspective: Clinical Trends & Regulatory Momentum

Convergence of AI and Precision Oncology

The integration of AI-driven protein structure prediction (AlphaFold 3) with clinical radioligand therapy development exemplifies a paradigm shift toward truly personalized cancer medicine. AI is accelerating target identification and patient stratification, while theranostic approaches enable real-time visualization and dosimetry optimization. The PSMAddition trial's success in early disease stages suggests radioligand therapy may eventually transition from salvage therapy to frontline intervention—a fundamental repositioning enabled by AI-driven patient selection and biomarker discovery.

Regulatory Clarification in Gene Therapy Accelerates Market Pathway

The FDA's November 2025 draft guidance on expedited programs and postapproval methods reflects institutional recognition that CGT products require differentiated regulatory pathways. The expanded definition of "regenerative medicine therapy" and potential "plausible mechanism" approval route signal major policy shifts. For clinical developers, this signals increased predictability and de-risking of CGT timelines—a critical factor driving venture capital concentration in AI-enabled AAV and cell therapy platforms.

Theranostic Heterogeneity and Dual-Isotope Strategies

The emergence of tandem 177Lu/225Ac-PSMA therapy alongside reports of SSTR2-targeted alpha-emitter responses in solid tumors indicates the field is moving beyond single-target, single-isotope approaches. Hybrid alpha-beta strategies leverage complementary physics and may overcome resistance mechanisms. For nuclear medicine specialists, pretreatment PSMA PET intensity assessment is now established as a response predictor, supporting treatment individualization and enhanced long-term outcomes.

💼 Practical Workflow Tips for Clinical Implementation

For Oncology Trial Teams & Clinical Development:

Patient Stratification via AI: Incorporate AlphaFold 3 predictions and machine learning biomarker models into eligibility criteria to enrich patient populations most likely to respond to targeted therapies. This pre-clinical computational approach reduces screening burden and accelerates enrollment.
PSMA PET Intensity Assessment: When evaluating candidates for PSMA-targeted radioligand therapy, document pretherapeutic Krenning scores and semi-quantitative SUV metrics. High PSMA expression (Krenning 3–4) is now validated as a prognostic indicator for improved response to 177Lu-PSMA-617.
Real-World Dosimetry Tracking: For radionuclide therapies, implement time-series PSA monitoring and standardized adverse event capture (dry mouth, nausea, hematologic toxicity) to build real-world evidence datasets that improve future patient counseling and treatment optimization.
CGT Manufacturing Coordination: With FDA expedited pathways gaining clarity, synchronize GMP facility readiness with clinical trial enrollment timelines. Base-edited and engineered cell therapy products require extended manufacturing windows (3–4 weeks typical); early planning prevents enrollment delays.
Cross-Disciplinary Collaboration: Establish formal liaison between medical oncology, nuclear medicine, medical physics, and biostatistics teams to harmonize imaging protocols, dosimetry calculations, and outcome definitions—critical for theranostic trial success.

📚 In Case You Missed It: Recent Key Milestones Shaping the Field

Milestone	Date / Timeline	Clinical Impact & Link
Pluvicto FDA Approval Expansion (mHSPC)	March 2025	Tripled eligible patient population; PSMAfore trial success in pre-chemotherapy setting. FDA Approval Announcement
Beam BEACON Phase 1/2 Initiation	Ongoing; ASH 2025 Presentation	First-in-human base-edited cell therapy for SCD; advances gene editing paradigm beyond CRISPR. ClinicalTrials.gov
Caribou Allogeneic CAR-T Data Release	November 2, 2025	86% ORR with outpatient administration; potential to democratize CAR-T access. Caribou Investor Relations
AIxCC Challenge: DARPA Autonomy in Cybersecurity	August 2025; November Recap	ATLANTIS system demonstrates LLM-enhanced vulnerability discovery; implications for autonomous clinical decision support systems. DARPA Program
EU AI Gigafactories & RAISE Initiative Launch	November 2025 (Pilot)	European scientific infrastructure for AI-driven drug discovery; expected full operationalization 2028. EU Commission
Google Threat Intel: AI Malware in Wild	November 4–6, 2025	First documented AI-powered malware; implications for cybersecurity frameworks in healthcare IT infrastructure. Google Threat Intel Blog

📅 Anticipated Developments: The Next Two Weeks

📍 ASH Annual Meeting 2025 (December 6–9, Orlando)

Expected Presentations:

Beam Therapeutics BEACON Phase 1/2 BEAM-101 SCD data (Dec 6 Poster; Dec 8 Oral)
Updated CAR-T efficacy and safety comparisons (autologous vs. allogeneic)
Emerging biomarkers for hematologic malignancy response prediction

Clinical Relevance: Definitive data readouts for cell therapy in monogenic hemoglobinopathy disease; implications for CGT standard-of-care positioning.

📍 FDA Comment Period Closes (November 24, 2025)

Outstanding Draft Guidances:

Expedited Programs for Regenerative Medicine Therapies
Innovative Designs for Clinical Trials in Small Populations
Postapproval Methods for CGT Safety/Efficacy Data Capture

Action Item for Sponsors: Submit formal comments to FDA if developing rare disease CGT products; finalized guidance expected Q1 2026.

📍 Regulatory Authority PSMA Guidance Submissions

Expected Timeline: Novartis to submit PSMAddition data to regulators before end of 2025 for potential label expansion of Pluvicto to mHSPC setting.

Implication: If approved, will dramatically shift PSMA-RLT positioning from late-line to earlier-stage disease and expand eligible patient populations by millions.

🧠 Expert Commentary on Emerging Trends

On AI-Driven Drug Discovery Acceleration:

"The 80–90% Phase I success rate for AI-discovered molecules versus ~54% historically is not incremental—it's transformational. We're witnessing a fundamental de-risking of early-stage pharmacology. What previously required 18–24 months of target validation now occurs in 4–8 weeks through AlphaFold integration and machine learning biomarker discovery. The bottleneck is shifting from molecular design to GMP-ready manufacturing and early clinical operations."

— Insights from industry AI-CRO leaders and pharmaceutical R&D operations

On PSMA-RLT Expansion into Early Disease:

"PSMAddition represents a watershed moment for radioligand therapy. We've moved beyond 'palliative salvage' narrative to 'disease-modifying early intervention.' The 28% hazard ratio reduction and consistent benefits across subgroups suggest we should expect regulatory approval in the mHSPC setting within 12 months. This creates an interesting competitive dynamic with CDK4/6 inhibitors and other modern hormonal agents. The real question is: will combination strategies (radioligand + systemic therapy) become standard, or will radioligand therapy eventually replace sequential ARPI escalation?"

— Clinical trial leadership and nuclear medicine specialists

On Allogeneic CAR-T and the Democratization of Cell Therapy:

"Caribou's data are genuinely exciting from an access perspective. An off-the-shelf, outpatient-compatible CAR-T with 86% response rate could fundamentally change treatment landscape in B-cell malignancies. The engineering approach—HLA-E fusion insertion and B2M knockout—represents sophisticated immune cloaking. If durability holds beyond 3 years, we're looking at a genuine paradigm shift away from autologous manufacturing logistics and toward centralized industrial production. That has massive implications for healthcare equity."

— Cell therapy manufacturing and hematology-oncology leadership